SecBot SecBot
PRESS-RELEASE ·Filed Mar 5, 2026

CRVS

Corvus Pharmaceuticals, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Traders should prepare for potential volatility following the March 12 earnings call, but this release itself contains no actionable financial information. Monitor for updates on clinical trial progress, cash runway, or changes in development strategy during the upcoming call.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$15.80
T+0 close · Mar 5, 2026 · via day close
Latest settled
−23.52%
T+60 · $12.08
Vs SPY
−36.30%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 6 $15.80entry
  2. T+1 · 8mo ago +0.60%α −0.24% · $15.89
  3. T+5 · 8mo ago −3.01%α −1.48% · $15.32
  4. T+20 · 8mo ago −6.87%α −4.82% · $14.71
  5. T+60 · 6mo ago −23.52%α −36.30% · $12.08
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Corvus Pharmaceuticals announced plans to host a conference call on March 12, 2026, to discuss its fourth quarter 2025 financial results and provide a business update. The press release contains no actual financial data, guidance, or material operational updates, only logistical details for the upcoming earnings call.

Key Facts

  • Corvus Pharmaceuticals will report Q4 2025 financial results on March 12, 2026.
  • The company will host a conference call and webcast at 4:30 pm ET.
  • No financial results, metrics, or business updates were disclosed in this release.
  • The company remains in clinical-stage development with soquelitinib in Phase 3 for PTCL and Phase 1 for atopic dermatitis.

Financial Impact

No financial data disclosed

Risk Factors

  • Lack of disclosed financials increases uncertainty ahead of earnings.
  • As a clinical-stage biotech, Corvus is dependent on trial outcomes and funding, with no near-term revenue from product sales.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3250632

Track record

15 reports on CRVS

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +2.61% at T+1 after the Mar 12, 2026 report. 2 of 3 went positive at some point.

Filters
  1. Nov 13, 20263d ago Insider Buy Neutral 3/10 Entry $11.20 Now $10.60 −5.36% settles Feb 12
  2. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $11.37 Now $10.60 −6.77% settles Feb 8
  3. Nov 5, 202611d ago 8-K Neutral 4/10 Entry $10.54 Now $10.60 +0.57% settles Feb 4
  4. Nov 5, 202611d ago Press Release Neutral 4/10 No price data
  5. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $10.57 Now $10.60 +0.28% settles Feb 2
  6. Sep 30, 20266w ago Press Release Neutral 3/10 Entry $10.93 Now $10.60 −3.02% settles Dec 28
  7. Aug 21, 202612w ago Institutional Cluster Bullish 6/10 Entry $14.46 to $10.60 Now $10.60 −26.69% ▼ −26.69% −23.33% vs SPY
  8. Jul 22, 202616w ago 8-K Neutral 2/10 Entry $13.68 to $9.85 Now $10.60 −22.51% ▼ −28.00% −32.55% vs SPY
  9. Jun 11, 202622w ago Institutional Cluster Neutral 3/10 Entry $11.60 to $14.39 Now $10.60 −8.62% ▲ +24.05% +19.66% vs SPY
  10. May 14, 202626w ago 8-K Bullish 7/10 Entry $13.66 to $13.74 Now $10.60 −22.37% ▲ +0.62% −2.97% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 5, 2026